FDA approves Matrix NDA for Zidovudine Tablets
Links shared publicly online about this topic.
- 448total visits
FDA approves Matrix NDA for Zidovudine Tablets
View full resource at news-medical.net
Tags: HIV, AIDS, HIV Medication, STD, Diet and Nutrition, FDA, Retrovir, News
Most Recently Shared on March 11, 2011 at 7:22 am By:
HIV/AIDS News: FDA approves Matrix NDA for Zidovudine Tablets: Mylan Inc. today announced that its subsidiary Ma... http://bit.ly/eG4LYX
Mylan Garners Approval of Water-Dispersible Zidovudine Tablets - MPR
empr.com — “Mylan--™s subsidiary, Matrix Laboratories, announced that under the President's Emergency Plan for AIDS Relief (PEPFAR), the FDA has approved water-dispersible zidovudine tablets, a generic version of Retrovir (GlaxoSmithKline).” View full resource at empr.com
Most Recently Shared on March 11, 2011 at 5:02 pm By:
MPR News: Mylan Garners Approval of Water-Dispersible Zidovudine Tablets: Mylan's subsidiary, Matrix Laboratorie... http://bit.ly/eYkQTV
Mylan Garners Approval of Water-Dispersible Zidovudine Tablets - ONA
oncologynurseadvisor.com — “Mylan--™s subsidiary, Matrix Laboratories, announced that under the President's Emergency Plan for AIDS Relief (PEPFAR), the FDA has approved water-dispersible zidovudine tablets, a generic version of Retrovir (GlaxoSmithKline).” View full resource at oncologynurseadvisor.com
Most Recently Shared on March 11, 2011 at 5:00 pm By:
OncologyNurseAdvisor Medical Publisher, Oncology, Nursing, and Medical Education
Mylan Garners Approval of Water-Dispersible Zidovudine Tablets http://goo.gl/fb/6EITN
Mylan Inc. - Mylan's Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
investor.mylan.com — “Mylan Inc. - Mylan's Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg” View full resource at investor.mylan.com
Most Recently Shared on March 10, 2011 at 3:42 pm By:
eyeonfda Pharma and Health Lawyer
Mylan's Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg - http://ow.ly/4bIzA
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR For Lamivudine And Zidovudine Tablets, 30 Mg/60 Mg
medicalnewstoday.com — “Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency” View full resource at medicalnewstoday.com
Most Recently Shared on January 21, 2011 at 5:05 pm By:
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR For Lamivudine And Zidovudine Tablets, 30 Mg/60 Mg http://mnt.to/3QhS #hivaids
FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA
news-medical.net — “Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.” View full resource at news-medical.net
Most Recently Shared on January 20, 2011 at 2:21 pm By:
HIV/AIDS News: FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA: Mylan In... http://bit.ly/dXASt0
Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR
news-medical.net — “Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.” View full resource at news-medical.net
Most Recently Shared on December 22, 2009 at 2:03 pm By:
Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR: Mylan Inc. today announced that... http://bit.ly/8Rmpkl
Matrix Laboratories receives tentative FDA approval for its NDA
news-medical.net — “Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.” View full resource at news-medical.net
Most Recently Shared on September 16, 2009 at 7:06 pm By:
HIV/AIDS News: Matrix Laboratories receives tentative FDA approval for its NDA: Mylan Inc. today a.. http://bit.ly/3N4P3h
Advertisement
